Global Biomarkers Market

Biomarkers Market Size, Share, Growth Analysis, By Product (Consumables, Services), By Type (Safety Biomarkers, Efficacy Biomarkers), By Research Area (Genomics, Proteomics), By Technology, By Disease Indication, By Application, By End User, By Region - Industry Forecast 2026-2033

Report ID: SQMIG35H2342 | Region: Global | Published Date: June, 2025
Pages: 196 | Tables: 92 | Figures: 76

Share your requirements to help us to customize the report.
   I acknowledge that I have read the Privacy Policy
Confidentiality

We respect your privacy rights and safeguard your personal information. We prevent the disclosure of personal information to third parties.

Our Clients

  • Schineder Electric
  • KSIA - Korea Semiconductor Industry Association
  • Hitachi Astemo Limited
  • Samsung Electronics
  • Halvo holdings
  • NTT corporation
  • AGC Inc
  • Siemens AG
  • Unilever
  • Merck Pharmaceuticals
  • Atlas Copco
  • Hologic - Medical Technology company
  • Novartis
  • Henkel
  • Reckitt
  • Schineder Electric
  • KSIA - Korea Semiconductor Industry Association
  • Hitachi Astemo Limited
  • Samsung Electronics
  • Halvo holdings
  • NTT corporation
  • AGC Inc
  • Siemens AG
  • Unilever
  • Merck Pharmaceuticals
  • Atlas Copco
  • Hologic - Medical Technology company
  • Novartis
  • Henkel
  • Reckitt

    • FAQs

    Global Biomarkers Market size was valued at USD 65.36 Billion in 2024 and is poised to grow from USD 73.4 Billion in 2025 to USD 185.66 Billion by 2033, growing at a CAGR of 12.3% during the forecast period (2026–2033).

    The biomarker market is highly competitive, and the leading players are employing strategic alliances, mergers, and acquisitions in order to strengthen pipelines and achieve geographical presence. Roche and Thermo Fisher are investing heavily in artificial intelligence platform-based biomarker discovery and companion diagnostics to create capabilities for personalized medicine. Firms are also looking to focus on the integration of multi-omics data and real-world evidence to achieve higher biomarker accuracy. This constantly evolving landscape is driving perpetual innovation to enable quick adaptation to evolving regulatory requirements and market conditions. 'F. Hoffmann-La Roche Ltd ', 'Abbott ', 'Agilent Technologies ', 'Bio-Rad Laboratories ', 'Bruker ', 'Charles River Laboratories ', 'CENTOGENE ', 'Enzo Biochem ', 'Epigenomics ', 'Eurofins Scientific ', 'EKF Diagnostics Holdings ', 'GE Healthcare ', 'Illumina, Inc. ', 'Merck ', 'MESO SCALE DIAGNOSTICS ', 'Charles River Laboratories ', 'Johnson & Johnson Services, Inc. ', 'PerkinElmer ', 'Siemens Healthineers ', 'QIAGEN ', 'Sino Biological ', 'Thermo Fisher Scientific'

    Increasing prevalence of chronic diseases such as cancer, cardiovascular diseases, and neurological disorders is among the major drivers of the biomarkers market. Detection and monitoring of these diseases are highly dependent on the identification of biomarkers, which enable early treatment and targeted therapy. As with the emphasis of health care systems globally turned towards preventive therapy, biomarkers have an important use in offering information about the onset of conditions as well as vulnerability to treatment. This demand also spurs demand for biomarker diagnostics and prognosis, stimulating investments in biomarker research as well as development of biomarker technology, thereby increasing the scope and applications of the market.

    Growing Adoption of Liquid Biopsy Technologies: Liquid biopsy is being quickly embraced as a quick, effective method of biomarker detection and monitoring, primarily in oncology. Liquid biopsy measures circulating tumor DNA (ctDNA) or other molecules found in the blood to facilitate early cancer detection, real-time treatment monitoring, and detection of resistance mutations. Ease of use compared to traditional tissue biopsies drives global clinical adoption. Enhanced sensitivity and specificity, and AI analytics integration, are optimizing liquid biopsies' performance. This is pushing expansion into non-cancer indications to other diseases, stimulating growth and investment in liquid biopsy platforms.

    North America dominates the world biomarkers market with strong healthcare infrastructure, high R&D spending, and rampant incidence of chronic diseases. The U.S. market alone would be valued at USD 124.49 billion by 2034 with a CAGR of 15.22%. The drivers on their list are genomics, proteomics, and bioinformatics advances, which would facilitate the discovery of new biomarkers. Government programs such as the Cancer Moonshot and Precision Medicine Initiative propel market growth by investing in biomarker R&D. The presence of large-scale biotech companies and favorable regulative frameworks also support biomarker-based therapeutics and diagnostics commercialization.

    Related Reports

    Digital Biomarkers Market
    Buy Now GET FREE SAMPLE
    Biomarker Technologies Market
    Buy Now GET FREE SAMPLE
    Cancer Biomarkers Market
    Buy Now GET FREE SAMPLE
    Neurological Biomarkers Market
    Buy Now GET FREE SAMPLE
    Central Nervous System Biomarkers Market
    Buy Now GET FREE SAMPLE
    Biopharmaceuticals Market
    Buy Now GET FREE SAMPLE
    Proteomics Market
    Buy Now GET FREE SAMPLE
    Molecular Diagnostics Market
    Buy Now GET FREE SAMPLE

    Feedback From Our Clients

    Global Biomarkers Market

    Report ID: SQMIG35H2342

    $5,300
    BUY NOW GET FREE SAMPLE